EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections

Edward J A Douglas iD, Sri W Wulandari, Scott D Lovell, Maisem Laabei iD

Microbial Biotechnology · 2023-07 · 16 (7) · 1456-1474

DOI: 10.1111/1751-7915.14268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbial Biotechnology, online erschienen am 13.05.2023. Verfasst von Edward J A Douglas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, University of Bath, Bath, UK. Hauptthemen laut MEDLINE: Drug Resistance, Multiple, Bacterial, Anti-Bacterial Agents, Drug Development, Staphylococcal Infections. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimicrobial resistance is a major obstacle for the treatment of infectious diseases and currently represents one of the most significant threats to global health. Staphylococcus aureus remains a formidable human pathogen with high mortality rates associated with severe systemic infections. S. aureus has become notorious as a multidrug resistant bacterium, which when combined with its extensive arsenal of virulence factors that exacerbate disease, culminates in an incredibly challenging pathogen to treat clinically. Compounding this major health issue is the lack of antibiotic discovery and development, with only two new classes of antibiotics approved for clinical use in the last 20 years. Combined efforts from the scientific community have reacted to the threat of dwindling treatment options to combat S. aureus disease in several innovative and exciting developments. This review describes current and future antimicrobial strategies aimed at treating staphylococcal colonization and/or disease, examining therapies that show significant promise at the preclinical development stage to approaches that are currently being investigated in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, Multiple, BacterialAnti-Bacterial AgentsDrug DevelopmentStaphylococcal InfectionsStaphylococcus aureusAntimicrobial Cationic PeptidesBiological ProductsAdjuvants, PharmaceuticDrug SynergismImmunoconjugatesPhage TherapyHumans

Substanzen

Antimicrobial Cationic PeptidesBiological ProductsAnti-Bacterial AgentsAdjuvants, PharmaceuticImmunoconjugates

Autor:innen und Institutionen

  • Department of Life Sciences, University of Bath, Bath, UK.

ORCID-Profile: Edward J A Douglas, Maisem Laabei

Förderung

  • Academy of Medical Sciences

Zitieren

APA

Douglas, E. J. A., Wulandari, S. W., Lovell, S. D., & Laabei, M. (2023). Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections. Microbial Biotechnology, 16(7), 1456-1474. https://doi.org/10.1111/1751-7915.14268

Vancouver

Douglas EJA, Wulandari SW, Lovell SD, Laabei M. Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections. Microbial Biotechnology. 2023;16(7):1456-1474. doi:10.1111/1751-7915.14268

BibTeX
@article{Douglas2023,
  author = {Douglas, Edward J A and Wulandari, Sri W and Lovell, Scott D and Laabei, Maisem},
  title = {Novel antimicrobial strategies to treat multi‐drug resistant Staphylococcus aureus infections},
  journal = {Microbial Biotechnology},
  year = {2023},
  volume = {16},
  number = {7},
  pages = {1456--1474},
  doi = {10.1111/1751-7915.14268}
}
Kostenlos starten →